Results 11 to 20 of about 34,994 (236)

Targeting FGFR inhibition in cholangiocarcinoma [PDF]

Cancer Treatment Reviews, 2021
Los colangiocarcinomas (CCA) son tumores raros pero agresivos de los conductos biliares, que a menudo se diagnostican en una etapa avanzada y tienen malos resultados en la terapia sistémica. Se han identificado alteraciones somáticas con implicaciones terapéuticas en casi la mitad de las CCA, en particular en la CCA intrahepática (iCCA), el subtipo que
Lipika Goyal, Sarinya Kongpetch, Valerie Crolley, John Bridgewater   +3 more
core   +6 more sources

FGFR Fusions in the Driver's Seat [PDF]

Cancer Discovery, 2013
Abstract Summary: Through a clinical deep sequencing protocol, Wu and colleagues have identified multiple FGFR fusion proteins in diverse cancers. Pharmacologic inhibition of FGFR suppressed the growth of FGFR fusion–positive tumor models, suggesting that these FGFR fusions are oncogenic drivers and highlighting the use of streamlined ...
Sabnis, Amit J, Bivona, Trever G
openaire   +6 more sources

Lighting up FGFR Signaling [PDF]

Chemistry & Biology, 2014
In this issue of Chemistry & Biology, Kim and colleagues describe their work on optogenetic control of fibroblast growth factor receptor (FGFR) signaling. By engineering a chimeric receptor, the authors demonstrate that FGFR intracellular signaling can be controlled in space and time by blue light.
Zhang, Kai, Cui, Bianxiao
openaire   +3 more sources

Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: Implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma

Pharmacological Research
Immune checkpoint inhibitors (ICIs) are essential for urothelial carcinoma (UC) treatment. Fibroblast growth factor receptor (FGFR) alterations, as common oncogenic drivers in UC, have been reported to drive T cell depletion of UC immune microenvironment
Yuxuan Song, Shan Jiang, Yun Peng, Caipeng Qin, Yiqing Du, Tao Xu   +5 more
doaj   +2 more sources

Targeting FGFR for cancer therapy

Journal of Hematology & Oncology
The FGFR signaling pathway is integral to cellular activities, including proliferation, differentiation, and survival. Dysregulation of this pathway is implicated in numerous human cancers, positioning FGFR as a prominent therapeutic target.
Pei Zhang, Lin Yue, QingQing Leng, Chen Chang, Cailing Gan, Tinghong Ye, Dan Cao   +6 more
doaj   +3 more sources

Dysregulation of the MACF1-Rab14/KIF16B-FGFR Vesicular Trafficking Axis Skews MSC Lineage Commitment in Glucocorticoid-Induced Osteoporosis. [PDF]

Adv Sci (Weinh)
Under normal conditions, MACF1 interacts with Rab14 and facilitates KIF16B‐mediated FGFR vesicle trafficking along microtubules to the plasma membrane, thereby supporting BMSC differentiation. In contrast, chronic GC exposure suppresses MACF1 expression, disrupting this transport and causing intracellular FGFR retention, which blunts osteogenic ...
Su P, Tian Y, Zhao F, Li J, Patil S, Zhu C, Tian Y, Wang J, Liu J, Xiang A, Guan H, Zhang L, Chen X, Qian A, Yu Q.   +14 more
europepmc   +2 more sources

Dual FGFR-targeting and pH-activable Smart Ruthenium-Peptide Conjugates for targeted therapy of Breast Cancer [PDF]

, 2023
Dysregulation of Fibroblast Growth Factor Receptors (FGFRs) signaling has been associated with breast cancer, yet employing FGFR-targeted delivery systems to improve cytotoxic agents is still sparsely exploited.
Marco, Sá, Inês, Pires, Jaime, A. S. Coelho, Miguel , Machuqueiro, João D. G. , Correia, Tânia , Morais, Filipa , Mendes, João , Franco Machado, Maria Helena, Garcia, M. Fátima , M. Piedade, María , Angeles Jiménez, Miguel , Silva, Fernanda , Marques   +12 more
core   +1 more source

Resistance to Selective FGFR Inhibitors in FGFR- Driven Urothelial Cancer

Cancer Discovery, 2023
Abstract Several fibroblast growth factor receptor (FGFR) inhibitors are approved or in clinical development for the treatment of FGFR-driven urothelial cancer, and molecular mechanisms of resistance leading to patient relapses have not been fully explored.
Francesco Facchinetti, Antoine Hollebecque, Floriane Braye, Damien Vasseur, Yoann Pradat, Rastislav Bahleda, Cédric Pobel, Ludovic Bigot, Olivier Déas, Juan David Florez Arango, Giorgia Guaitoli, Hayato Mizuta, David Combarel, Lambros Tselikas, Stefan Michiels, Sergey I. Nikolaev, Jean-Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Ken A. Olaussen, Yohann Loriot, Luc Friboulet   +21 more
openaire   +3 more sources

Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. [PDF]

, 2022
BACKGROUND Patients with advanced squamous-cell lung cancer (SQCLC) frequently (46%) exhibit tumor overexpression of fibroblast growth factor receptor (FGFR) messenger ribonucleic acid (mRNA). Rogaratinib is a novel oral pan-FGFR inhibitor with a good
Calgua, Byron, Waibel, Christine, Jermann, Philip M, Haefliger, Simon, Alborelli, Ilaria, Joerger, Markus, Mach, Nicolas, Addeo, Alfredo, Savic-Prince, Spasenija, Holer, Lisa, Fernandez, Eugenio, Rothschild, Sacha I, Mauti, Laetitia, Früh, Martin, Mark, Michael, Schneider, Martina   +15 more
core   +2 more sources

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.

, 2016
FGFR1 and FGFR2 are amplified in many tumor types, yet what determines response to FGFR inhibition in amplified cancers is unknown. In a translational clinical trial, we show that gastric cancers with high-level clonal FGFR2 amplification have a high ...
E. Kilgour (7782980), C. Geh (7782986), S. Chua (7662866), A. Gillbanks (7783010), J. Campbell (7758590), S. R. Johnston (7783001), K. Fenwick (7710497), A. Swain (7782998), R. Cutts (7782992), K. Sumpter (7783007), C. Rooney (7782989), M. Ajaz (7783004), D. Cunningham (2534575), G. Brown (569084), N. R. Smith (7782983), C. Peckitt (7782977), M. T. Herrera-Abreu (7782971), S. Popat (7783016), J. Ning (7782995), E. Smyth (7782965), D. Watkins (3494225), I. Chau (7783013), N. Tarazona (7782974), Anne Thomas (90885), I. S. Babina (7782968), N. C. Turner (7783019), A. Pearson (7649903)   +26 more
core   +8 more sources